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I. INTRODUCTION 
      The present work deals with the studies carried out on the development, optimization and 
validation of RP-HPLC method for the simultaneous estimation of Olanzapine and Fluoxetine 
Hcl in Pharmaceutical dosage form. 
Analytical chemistry is a branch of chemistry that deals with the separation, identification 
and determination of components in a sample. It is the science of making quantitative 
measurements, which requires background knowledge of chemical and physical concepts
2
. 
I.I Analytical chemistry 
 Analytical chemistry may be defined as the “Science and art of determining the 
composition of materials in terms of the elements or compounds contained” Pharmaceutical 
analysis plays a major role today, and it can be considered as an interdisciplinary subject. 
Pharmaceutical analysis derives its principles from various branches of science like Chemistry, 
Physics, Microbiology, Nuclear Science, Electronics, etc. Analytical method is a specific 
application of a technique to solve an analytical problem. Analytical instrumentation plays an 
important role in the production and evaluation of new products and in the protection of 
consumers and the environment. This instrumentation provides the lower detection limits 
required to assure safe foods, drugs, water and air. 
Pharmaceutical analysis techniques are applied mainly in two areas
1 
 Traditionally, analytical chemistry has been split into two main types, 
Qualitative Analysis – Information regarding the presence or absence of one or more 
components of the sample is taken in to account  
Quantitative Analysis – Amount of analyte present is determined using appropriate analytical     
method     
Classification of Instrumental Methods of Analysis 
 The instrumental techniques are classified as 
 Spectroscopic Techniques 
 Electrochemical Techniques 
 Chromatographical Techniques 
 Miscellaneous Techniques 
 Hyphenated Techniques 
A) Spectroscopic Techniques 
Spectroscopy is the measurement and interpretation of electromagnetic radiation absorbed, 
scattered, or emitted by atoms, molecules or other chemical species. 
 Examples:   
 UV Spectrophotometry  
 Atomic Spectrometry  
 Infrared Spectrometry 
 Raman Spectrometry 
 X-Ray Spectrometry  
 Nuclear Magnetic Resonance Spectrometry 
B) Electrochemical Techniques 
      In this, each basic electrical measurement of current like resistance and voltage has been 
measured alone or in combination for analytical purposes. 
 
Examples:  
 Potentiometric Techniques. 
 Voltametric Techniques. 
 Amperometric Techniques.  
 Electrogravimetry. 
 Conductance Techniques.  
 
C) Chromatographic Techniques 
          Chromatography provides versatility in the type of analysis that can be performed. This 
versatility, due to the wide choice of materials for the stationary and mobile phase, makes it 
possible to separate molecules that differ only slightly in their physical and chemical properties 
and can also be quantitatively estimated.  
    Examples: 
 Gas Chromatography 
 High performance Liquid Chromatography 
 Thin Layer Chromatography 
D) Miscellaneous Techniques 
    Examples: 
 Thermal Analysis 
 Mass Spectrometry 
 Kinetic Techniques 
E) Hyphenated Techniques 
         Separation of mixtures by chromatographic processes is a central part of analytical and 
preparative chemistry. The direct conjunction of these chromatographic techniques with 
spectroscopic examination of the separated fractions constitutes several powerful analytical 
partnerships. 
Examples:  
 GC-MS (Gas Chromatography – Mass Spectrometry) 
 ICP-MS (Inductivity Coupled Plasma Mass Spectrometry) 
 GC-IR (Gas Chromatography – Infrared Spectroscopy) 
 MS-MS (Mass Spectrometry – Mass Spectrometry)  
 
CHROMATOGRAPHY 
              Chromatography is a non-destructive procedure for resolving a multi-components 
mixture of trace, minor, or major constituents into its individual fractions. Different variations 
may be applied to solids, liquids, and gases. While chromatography may be applied both 
quantitatively, it is primarily a separating tool. 
               Russian botanist Michael Tswett invented chromatography as a separation           
technique.  He described in detail the separation of pigments, the colored substances by filtration 
through column, followed by developments with pure solvents.  The first paper of Tswett, was 
published in 1903, contains a study of more than 100 absorbents used in conjunction with several 
different solvents. 
            Other developments in the progress of chromatography were the presentation of 
gas-liquid chromatography by James and Martin.  Despite the exciting possibilities that Tswett‟s 
possibilities observation evoked, little work was carried out until 1931 when Kuhn and Lederer 
repeated Tswett‟s experiments using alumina and calcium carbonate to separate plant pigments.   
 
The techniques were basically liquid-solid absorption chromatography (LSC); it was not 
until the late 1930‟s.  In 1941, Martin and Synge introduced liquid-liquid partition 
chromatography (LLC) and in that publication Martin and Synge also suggested the possibilities 
of gas chromatography (GC).  
                In the early 1950‟s, James and Martin started work on the original suggestion of 
Martin and Synge developed the first gas chromatograph. Between 1954 and 1962 gas 
chromatography (GLC) developed at remarkable rate and by 1962, became a mature analytical 
technique. 
                  The renaissance of LC started in the late 1960‟s and by the early 1980‟s LC had also 
become an established analytical technique used generally for the separation and analysis of a 
wide range of complex mixtures including many that had previously been analyzed by GC.  
Some of the more recent developments in LC may well provoke further synergistic 
developments in GC but further progress in LC appears at this time to be relatively slow just as it 
has been with over the last two decades.  
CLASSIFICATION OF CHROMATOGRPHY 
Based on the principle involved 
 Absorption Chromatography 
 Partition Chromatography 
 Ion-exchange Chromatography  
 Permeation Chromatography  
 Affinity Chromatography  
 Electrophoretic Chromatography  
 
Types of Chromatography 
           Chromatography characterized as a separation method based on the differential migration of 
solute through a system of two phases, one is mobile phase another one is stationary phase.  
Chromatography is a technique by which the components in a sample, carried by the liquid or gaseous 
phase, are resolved by sorption, desorption steps on the stationary phase. 
  
    Classification of various types of Chromatographic methods 
 
Technique Stationary phase Mobile phase 
Column chromatography Solid Liquid 
Partition chromatography Liquid Liquid 
Paper chromatography Liquid Liquid 
Thin layer chromatography Liquid (or) solid Liquid 
Gas-liquid chromatography Liquid Gas 
Gas-solid chromatography Solid Gas 
Ion-exchange chromatography Solid Liquid 
 
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
               High Performance Liquid Chromatography is the most widely used of all of the 
analytical separation techniques with the annual sales of HPLC equipment approaching the 
billion-dollar mark. The reason for the popularity of the method is its sensitivity, its suitability 
for separating non-volatile or even thermally fragile ones, its ready adaptability to quantitative 
determinations and above all its wide spread applicability to substances that are of primary 
interest to industry, to many fields of science, biomedical applications  and to the public. 
Examples of such materials include amino acids, nucleic acids hydrocarbons, carbohydrates, 
drugs, threnodies, pesticides, antibiotics, and metal organic species. The development of the 
open-column methods, i.e. paper chromatography (in the 1940s) and thin layer chromatography 
(in the 1950s), greatly improved the speed and resolution of LC, but there were still serious 
limitations compared to modern LC methods.  In that, analysis times were long, resolution was 
poor and quantitative analysis, preparative separations and automation were difficult.  The rapid 
growth of HPLC has been facilitated by the development of reliable, moderately priced 
instrumentation and efficient columns. Now, HPLC analysis is most widely used instrumental 
method for assays.  
      
 
 
 
             
 
 
  Schematic diagram of HPLC 
 
 
 
 HPLC BASIC INSTRUMENTATION 
 
TYPES OF HPLC 
Based on Modes of Chromatography: 
 Normal phase chromatography 
 Reverse phase chromatography 
 
Based on Principle of Separation: 
 Adsorption chromatography 
 Ion exchange chromatography 
 Size exclusion chromatography 
 Affinity chromatography 
 Chiral phase chromatography 
Base on Elution Technique: 
 Isocratic separation  
 Gradient separation 
Based on the Scale of Operation: 
 Analytical HPLC  
 Preparative HPLC 
a) Normal phase chromatography 
               Normal phase chromatography is chromatographic technique that uses organic solvents 
for mobile phase and a polar stationary phase.  Here, the less polar compound elutes faster than 
the more polar compound. 
b) Reverse phase chromatograph since 1960‟s chromatographers started modifying the polar 
nature of silanol group by chemically reacting silica with organic silanes. The objective was to 
make less polar or non-polar so that polar solvents can be used to separate water-soluble polar 
compounds. Since the ionic nature of the chemically modified silica is now reversed i.e. it is    
non-polar or the nature of the phase is reversed. The chromatographic separation carried out with 
such silica is referred to as reversed- phase chromatography.
17 
 A large number of chemically bonded stationary phases based on silica are available 
commercially. There are some of the functional groups bonded in chemically modified silica. 
Silica based stationary phases are still most popular in reversed phase chromatography however 
other absorbents based on polymer (styrene-di-vinyl benzene copolymer) are slowly gaining 
ground. 
 
 
 
 
 
I. 2 Normal – Reverse Phase Chromatography 
 
 
 
 
 
 
 
 
 
         As a general rule the retention increases with increasing contact area between sample 
molecule and stationary phase i.e. with increasing number of water molecules, which are 
released during the adsorption of a compound. Branched chain compounds are eluted more 
rapidly than their corresponding normal isomers. 
 In reversed phase systems the strong attractive forces between water molecules arising 
from the 3 - dimensional inter molecular hydrogen bonded network, from a structure of water 
that must be distorted or disrupted when a solute is dissolved. Only higher polar or ionic solutes 
can interact with the water structure. Non- polar solutes are squeezed out of the mobile phase and 
are relatively insoluble in it but with the hydrocarbon moieties of the stationary phase, they get 
adsorbed. 
          
                 Reverse phase chromatography - a bonded phase chromatography technique, uses 
water as base solvent.  Separation is based on solvent strength and selectivity.  Separation is also 
affected by column temperature and pH.  In general, the more polar compounds elute faster than 
the less polar compounds. UV detection is the most common detection technique used.
3
  
 Certain limitations of RP-HPLC are: 
 Compounds much more polar than the compound of interest may be masked (eluted together) in the 
solvent front / void volume. 
 Compounds very less polar than the analyte may elute either late during the chromatographic run or are 
retained in the column. 
 The compounds with lower UV extinction coefficients or different wavelengths maxima may not be 
detectable at the low level relative to the visibility of the analyte since only one or two wavelengths are 
monitored. 
c) Size exclusion chromatography 
             It is also known as gel permeation or filtration chromatography.  Here, separation is 
based on the molecular size or hydrodynamic volume of the components. The stationary phase is 
a wide pore gel that can separate molecules on the basis of their size and shape, the largest 
molecules traveling most rapidly through the system.  So, molecules that are too large for the 
pores of the porous packing material on the column elute first, small molecules that enter the 
pores elute last, and the elution rates of the rest depend on their relative size    
d) Ion Exchange Chromatography 
             The stationary phase is an ion exchange resin, and separations are governed by the 
strength of the interactions between solute ions and the exchange sites on the resin.  An ion 
exchange resin consists of an insoluble, rigid three-dimensional matrix, for example polystyrene 
cross-linked with a small amount of divinylbenzene to produce mechanical stability.  The surface 
of this matrix contains ionizable sites that can carry a positive or a negative charge.  Each of  
these sites also require an oppositely charged ion for overall neutrality.  If the ionizable sites are 
positively charged, the counter ion is an anion and the resin will exchange anions from solution. 
e) Ion pair /Affinity chromatography 
              Separation is based on chemical interaction, specific to the target species. The more 
popular reverse phase mode uses a buffer and an added counter ion of opposite charge to the 
sample with separation being influenced by pH, ion strength, temperature, concentration and 
organic modifier. Affinity chromatography, commonly for macromolecules employs a ligand 
(biologically active molecule bonded covalently to the solid matrix), which interacts with its 
homologous antigens as a reversible complex that can be eluted by changing buffer conditions. 
f) Chiral Chromatography 
Chirality plays an important role in pharmaceutical industry. It is mainly because of the 
enantiomers exhibit different pharmacological and toxicological properties in living systems. A 
tragic example was thalidomide, a sedative and sleep inducing drug, which caused serious 
malformations in new borns of women who consumed it during an early phase of pregnancy. 
Later, it was realized that S-(-) enantiomer of thalidomide possess teratogenic action and has no 
importance for the desired sedative or sleep inducing property. Very often the enantiomers of 
racemic drugs possess different pharmacological effects. For example, S-(-)-propranolol is 
considerably more active than its R-(+) enantiomer. The anesthetic ketamine is generally 
administered as a racemate. 
Advantages and disadvantages of the mobile phase additives 
Advantages Disadvantages 
1. Less expensive conventional LC 
columns can be used 
2. A wide variety of possible additives 
are available 
3. Different selectivities from the chiral   
phases can be obtained. 
 
1. Many chiral additives are costly, 
and sometimes have to be synthesized. 
2. The mode of operation is complex 
3. Inconvenient for preparative   
    applications because the chiral   
    additive must be removed from the    
     Enantiomeric solutes. 
 Schematic diagram of High Performance Liquid Chromatography 
 
 
 INSTRUMENTATION: 
The essential parts of the High Performance Liquid Chromatography are: 
 Solvent reservoir  
 Mobile phase 
 Pump system 
 Sample Injection System 
 Column 
 Detector 
 
Solvent reservoir  
A modern HPLC apparatus is equipped with one or more glass or stainless steel 
reservoirs.  The reservoir is often equipped with an online degasser which removes the dissolved 
gasses usually oxygen and nitrogen, which interfere by forming bubbles. Degasser may consist 
of vacuum pumping system, distillation system, system devices for heating, and solvent stirrer. 
Mobile phase 
One of the greatest advantages of HPLC is versatility afforded by liquid mobile phase.  
Not only can different parameter be varied when the mobile phase is liquid, but also the solute 
can interact with the mobile phase as well as with the stationary phase.  Sufficient solubility of 
solute molecules in the mobile phase must be ensured in order to prevent precipitation. 
Pumping system 
            The function of the pump in HPLC is to pass mobile phase through the column at a 
controlled flow rate.  Features of an ideal pumping system include: 
Generating pressure from 6000 psi to 10000 psi.Pulse free output. 
 
Flow rates ranging from 0.1 to 10 ml/min. Flow control and reproducibility of 0.5% relative or 
better. Corrosion resistant components. 
 
HPLC pump can be classified in to the following groups according to the manner in which they 
operate:  
 Constant flow rate pump (or) constant displacement pump 
                    i) Reciprocating piston pump 
                    ii) Syringe drive pump 
 Constant pressure pump 
                     i) Simple gas displacement pump 
                      ii) Pneumatic amplifier pump  
1. Reciprocating pump 
          Reciprocating pumps usually consist of a small chamber in which the solvent is pumped 
by the back and forth motion of a motor driven piston.  Two check valves control the flow of 
solvent.  Reciprocating pumps have a disadvantage of producing pulsed flow, which must be 
damped as its presence is manifested as base line noise on the chromatogram.  Advantages of 
this pump include their small internal volume, high output pressure, ready adaptability to 
gradient elution, and independent of column backpressure and viscosity of solvent 
Piston pumps 
       
  
2. Displacement pump 
             Displacement pumps usually consist of large syringe like chambers equipped with a 
plunger that is activated by a screw driver mechanism powered by stepping motor.  
Displacement pumps also produce a flow that tends to be independent of viscosity and 
backpressure.  In addition, the output is pulse free. Disadvantages include limited solvent 
capacity (250 ml) and considerable inconvenience when solvents must be changed. 
3. Pneumatic pumps 
           In pneumatic pumps, the mobile phase is contained in a collapsible container housed in a 
vessel that can be pressurized by a compressor gas.  Pumps of this kind are inexpensive and 
pulse free.  They suffer from limited capacity, pressure output, dependence of flow rate on 
solvent viscosity and column backpressure.  In addition, they are not amenable to gradient 
elution and are limited to pressures less than about 2000 psi. 
 
Sample injection system 
             The limiting factor in the precision of LC measurements lie in reproducibility with which 
samples are introduced into the column packing.  The earliest and simple means of sample 
introduction was syringe injection through a self-sealing electrometric septum.  In stop flow 
injections, the flow of solvent is stopped momentarily, and fitting at column head is removed and 
the sample is injected directly into the head of column packing.  After replacing the fitting the 
system is again pressurized.  
 
 Sample   injection 
system 
 
 
 
 
 
 
  Columns 
                   The columns most commonly used are made with 316-grade stainless steel (a Cr-Ni-
Mo steel, relatively inert to chemical corrosion).  The inside of the stainless steel tube should be 
as smooth as possible, so the tubes are precision drilled or electro-polished after manufacture.  
Common dimensions are 6.35 mm external diameter, 4.6 mm internal diameter and up to 25 cm 
long.  The columns can be packed with 10, 5, 4 or 3 µm diameter particles.   
              At the top of the column, there is a distributor for directing the injected sample to the 
center of the column and then a stainless steel gauze or frit on top of the packing.  At the lower 
end there is another frit to retain the packing, and then, for the 4.6 mm type, a reducing union 
and a short length of 0.25 mm (0.01 in.) i.e. tubing to connect the column to the detector.   
 
    Materials other than stainless steel that are used for columns include glass, glass lined steel 
tube and polyethene or other inert plastics. 
              
 
  Properties of particles in various types of columns 
1 Analytical columns  
                The majority of LC columns range in length from 5 to 30 cm. The inner diameter of 
liquid columns is often 4 to 5 mm.  Most common particle size of packing is 5 to 10 µm.  
Columns of this type contain 40000 - 60000 plates per meter 
2 Preparative columns 
               Preparative columns are typically 2-5 cm in diameter and 25 cm long with packing of 
15-100-µm diameter.  Columns for large-scale work can be 20-30 cm in diameter and 60 cm 
long, using flow rates up to 1000 cc min-1.  The commercial systems can be used isocratically or 
with gradients, and allow small-scale development and preparative separation to be done using 
the same system.  
 
 
    3 Guard columns       
              Usually, a short guard column is introduced before the analytical column to increase its 
life.  It removes particulate matter, contaminants from the solvents and also sample components     
that bind irreversibly to stationary phase.  The composition of the guard column packing should 
be closely similar to that of analytical columns 
  
                        
 
  Partisil® High performance liquid chromatography (HPLC) columns 
   Detectors 
                 The function of the detector in HPLC is to monitor the mobile phase emerging from 
the column.  The output of the detector is an electrical signal that is proportional to some 
property of the mobile phase and/or the solutes. 
LC detectors are basically of two types. 
 
    
 
 
   
  LC Detector 
 
 
 
 
 
 
 
   
 
               Bulk property detectors respond to mobile phase bulk property such as refractive index, 
dielectric constant or density. 
            Solute property detectors respond to some property of solutes, such as UV absorbing, 
fluorescence, diffusion current, which are not possessed by the mobile phase. 
Most common HPLC detectors 
 UV-Visible absorbance detector (UV-VIS) 
 Photo-diode array detector (PDA) 
 Fluorescence detector 
 Electrochemical (ECD) 
 Refractive Index (RI) 
 Mass detectors (MS) 
 Conductometric detector 
 Chiral detector (Polarimetric & circular dichrosim) 
 Evaporative Light scattering detector (ELSD) 
 Radiochemical detection                                                      
UV Detector 
1. UV absorbing detector 
The general applicability and ease of operation of UV-Visible absorbance detectors have 
made it most popular in LC.  It measures the absorbance of the monochromatic light by the 
solute according to the Beer-Lambert‟s law. 
Where, „I‟ is the intensity of the transmitted light, „Io‟ is intensity in the absence of the analyte.  
„a‟ is molar absorpitivity of analyte at the wavelength used, „b‟ is the length of the optical cell 
used and „c‟ is the concentration of the analyte  
 
 
 
 
2. Photodiode array detectors 
             In Photo Diode Array detector, the single detecting of UV detector has been replaced by 
an array of solid state detecting elements (photo-diodes).  These detectors typically have large 
numbers of diodes in array (256, 512, and 1024).  In PDA, polychromatic radiation, after passing 
through the sample, is dispersed by a fixed grating and then falls on to an array of photodiodes.  
Each diode measures a narrow band of wavelengths in the spectrum, thus the PDA has parallel 
data acquisition, all points in the spectrum being measured simultaneously.  The spectrum of 
each peak in the chromatogram can be stored and subsequently compared with standard spectra, 
which facilitates the identification of peaks. 
 
This system is superior to other detection systems as: 
           There are no moving parts to wear out, wavelength-resetting errors are reduced and the 
instrument is likely to require less maintenance than does a conventional spectrophotometer. 
I = I0 10 -abc 
             The ability to make multiwavelength measurements and the speed of data acquisition 
mean that various signal-averaging techniques can be used to reduce noise and improve 
sensitivity. 
 
 
 
 
 
 
 
 
  Photodiode array detector  
3 Peak purity by PDA detector: 
           When two compounds elute very close to each other, they appear as one peak.  This can 
be recognized by a difference of the spectra recorded on the two flanks of the peak, provided the 
two compounds have different absorption spectra.  When PDA is combined with a separating 
column, three dimensions become available; wavelength, intensity and chromatographic 
retention. The spectra obtained must be sufficiently different as specified by their correlation 
coefficients.  Even with a value under 0.9, superimposed peaks can be calculated and evaluated 
in a three dimensional space without substantial loss in terms of accuracy and precision to know 
the purity of a particular peak.  
   4. Fluorescence detectors 
          Many compounds are capable of absorbing UV radiation and subsequently emitting 
radiation of a longer wavelength, either instantly (fluorescence) or after a time delay 
(phosphorescence).  Such compounds are suitable for fluorescent detection.    
          Radiation from a xenon or deuterium source is focused on the flow cell.  The simplest 
detectors employ a mercury excitation source and one or more filters to isolate the band of 
emitted radiation.  An interchangeable filter allows different excitation wavelengths to be used.  
The fluorescent radiation is emitted by the sample in all directions, but is usually measured at 90º 
to the incident beam.  FD for HPLC is similar in design to the fluorometers or 
spectrofluorometer. 
 
                 
 
 
                
 Block diagram of Fluorescence detector 
 
5. Refractive index detectors 
                     RI detectors are bulk property detectors in which the solvent passes through one 
half of the cell on its way to the column.  A glass plate mounted at an angle such that bending of 
the incident beam occurs if the two solutions differ in refractive index separates the two  
 
Compartments.  The resulting displacement of the beam with respect to the photosensitive 
surface of the detectors causes variation in the output signal. 
6. Evaporative light scattering detectors (ELSD) 
                Evaporative Light Scattering Detection is the preferred concentration detection method 
for Liquid Chromatography.  Their principal requirement is that the analyte should be less 
volatile than the mobile phase.  An ELSD cannot detect highly volatile analytes.  In this detector, 
the column effluent is passed into a nebuliser where, it is converted into fine mist by a flow of 
nitrogen.  The fine droplets are then carried through a controlled temperature drift tube where, 
evaporation of mobile phase occurs leading to the formation of fine particles of the analyte. The 
cloud of analyte particles then passes through a laser beam.  The scattered radiation is detected at 
right angle to the flow by a silicon photo diode. 
7. Electrochemical detectors  
              Electrochemical detection (ECD) is based on the transfer of electrons between either 
oxidisable / reducible molecule in the solution and a solid conductor.  ECD measure either the 
conductance of the eluent or the current associated with the oxidation or reduction of solutes.  To 
be capable of detection using the first method the solutes must be ionic, and using the second 
method the solutes must be relatively easy to oxidize or reduce. 
8. Conductivity Detectors 
               The conductivity detectors are used for the detection of inorganic or organic ions, 
usually after separation by ion exchange chromatography.  These detectors oxidize or reduce 
only a small quantity of the solute, so the currents observed are very small (nanoamps). 
 
ANALYTICAL METHOD DEVELOPMENT 
             Methods are developed for new products when no official methods are available.  
Alternate methods for existing (non-Pharmacopoeia) products are developed to reduce the cost 
and time for better precision and ruggedness. Trial runs are conducted, method is optimized and 
validated.  When alternate method proposed is intended to replace the existing procedure 
comparative laboratory data including merit / demerits are made available. 
Steps of method development 
           Documentation starts at the very beginning of the development process, a system for full 
documentation of the development studies must be established. All data relating to these studies 
must be recorded in laboratory notebook or an electronic database. 
1. Analyte standard characterization 
          All known information about the analyte and its structure is collected i.e., physical and 
chemical properties. 
The standard analyte (≈100% purity) is obtained.  Necessary arrangement is made for the proper 
storage (refrigerator, dessicators, and freezer). 
         When multiple components are to be analyzed in the sample matrix, the number of 
components is noted, data is assembled and the availability of standards for each one is 
determined. 
Only those methods (spectroscopic, MS, GC, HPLC etc.,) that are compatible with sample 
stability are considered.  
 
     2. Method requirements 
          The goals or requirements of the analytical method that need to be developed are 
considered and the analytical figures of merit are defined.  The required detection limits, 
selectivity, linearity, range, accuracy and precision are defined.  
3. Literature search and prior methodology 
           The literature for all types of information related to the analyte is surveyed. For synthesis, 
physical and chemical properties, solubility and relevant analytical methods.  Books, periodicals, 
chemical manufacturers and regulatory agency compendia such as USP / NF, AOAC and ASTM 
publications are reviewed.  Chemical Abstracts Service (CAS) automated computerized literature 
searches are convenient. 
4. Choosing a method 
            Using the information in the literatures and prints, methodology is adapted.  The methods 
are modified wherever necessary. Sometimes it is necessary to acquire additional instrumentation 
to reproduce, modify, improve or validate existing methods for in-house analytes and samples. 
           If there are no prior methods for the analyte in the literature, from analogy, the 
compounds that are similar in structure and chemical properties are investigated and are worked 
out. There is usually one compound for which analytical method already exist that is similar to 
the analyte of interest. 
 
 
5. Instrumental setup and initial studies 
                The required instrumentation is setup.  Installation, operational and performance 
qualification of instrumentation using laboratory standard operating procedures (SOP‟s) are 
verified. 
               Always new consumables (e.g. solvents, filters and gases) are used, for example, 
method development is never started, on a HPLC column that has been used earlier.  
The analyte standard in a suitable injection / introduction solution and in known 
concentrations and solvents are prepared.  It is important to start with an authentic, known 
standard rather than with a complex sample matrix.  If the sample is extremely close to the 
standard (e.g., bulk drug), then it is possible to start work with the actual sample. 
6. Optimization 
              During optimization one parameter is changed at a time, and set of conditions are 
isolated, rather than using a trial and error approach.  Work has been done from an organized 
methodical plan, and every step is documented (in a lab notebook) in case of dead ends. 
7. Documentation of analytical figures of merit 
             The originally determined analytical figures of merit limit of quantitation (LOQ), Limit 
of detection (LOD), linearity, time per analysis, cost, sample preparation etc., are documented. 
8. Evaluation of method development with actual samples 
               The sample solution should lead to unequivocal, absolute identification of the analyte 
peak of interest apart from all other matrix components.  
9. Determination of percent recovery of actual sample and demonstration of quantitative 
sample analysis 
            Percent recovery of spiked, authentic standard analyte into a sample matrix that is shown 
to contain no analyte is determined.  Reproducibility of recovery (average +/- standard deviation) 
from sample to sample and whether recovery has been optimized has been shown.  It is not 
necessary to obtain 100% recovery as long as the results are reproducible and known with a high 
degree of certainty. 
            The validity of analytical method can be verified only by laboratory studies.  Therefore 
documentation of the successful completion of such studies is a basic requirement for 
determining whether a method is suitable for its intended applications.  
         
Method Validation 
Validation 
              Validation of an analytical method is the process by which it is established, by 
laboratory studies, that the performance characteristics of the method meet the requirements for 
the intended analytical applications  
Validation is defined as follows by different agencies 
Food and Drug administration (FDA) 
              Establishing documentation evidence, which provides a high degree of assurance that 
specific process, will consistently produce a product meeting its predetermined specification and 
quality attributes. 
World Health Organization (WHO) 
           Action of providing that any procedure, process, equipment, material, activity, or system 
actually leads to the expected results 
European Committee                
               Action of providing in accordance with the principles of good manufacturing practice 
that any procedure, process, equipment, material, activity or system actually leads to the 
expected results. In brief validation is a key process for effective Quality Assurance. 
Reasons for Validation  
                There are two important reasons for validating assays in the pharmaceutical industry. 
The first, and by for the most important, is that assay validation is an integral part of the quality-
control system. The second is that current good manufacturing practice regulation requires assay 
validation.  
           
Steps followed for validation procedures 
1. Proposed protocols or parameters for validations are established. 
2. Experimental studies are conducted. 
3. Analytical results are evaluated. 
4. Statistical evaluation is carried out. 
5. Report is prepared documenting all the results. 
                Objective and Parameters of Analytical Method Validation 
         The objective of validation of an analytical procedure is to demonstrate that it is suitable 
for its intended purpose.  According to ICH guidelines, typical analytical performance 
characteristics that should be considered in the validation of the types of methods are  
(a) Recovery  
(b) Response function 
(c)  Sensitivity 
(d)  Precision  
(e)  Accuracy  
(f) Limit of detection 
(g)  Limit of quantitation  
(h) Ruggedness 
(i)  Robustness 
(j) Stability  
(k) System Suitability 
(l) Repeatability 
(m) Specificity 
 
 
 (a) Recovery 
      The absolute recovery of analytical method is measured as the response of a processed 
spiked matrix standard expressed as a percentage of the response of pure standard, which has not 
been subjected to sample pre-treatment and indicates whether the method provides a response for 
the entire amount of analyte that is present in the sample. It is best established by comparing the 
responses of extracted samples at low, medium and high concentrations in replicates of at least 6 
with those non-extracted standards, which represent    If an internal standard is used, its recovery 
should be determined independently at the concentration levels used in the method. 
 
 
 
 
(b) Response of function 
           In chromatographic methods of analysis, peak area or peak height may be used as 
response function to define the linear relationship with concentration known as the calibration 
model. It is essential to verify the calibration model selected to ensure that it adequately 
describes the relationship between response function (Y) and concentration (X). 
(c) Sensitivity 
       The method is said to be sensitive if small changes in concentration cause large changes in 
response function. The sensitivity of an analytical method is determined from the slope of the 
calibration line. The limits of quantification (LOQ) or working dynamic range of bio analytical 
method are defined as the highest and lowest concentrations, which can determined with 
acceptable accuracy.                  
    It is suggested that, this be set at + 15% for both the upper and lower limit of quantitation 
respectively. Any sample concentration that falls outside the calibration range cannot be 
interpolated from the calibration line and extrapolation of the calibration curve is discouraged. If 
the concentration is over range, the sample should be diluted in drug-free matrix and re-assayed.  
 
                                                  Response an analyte spike into matrix (processed) 
         Absolute Recovery =                                                                                           x 100  
             Response of analyte of pure standard (unprocessed) 
 
 
(d) Precision 
              The precision of an analytical method is a measure of the random error and is defined as 
the agreement between replicate measurements of the same sample. It is expressed as the 
percentage coefficient of variation (%CV) or relative standard deviation (RSD) of the replicate 
measurements. 
%CV = Standard deviation/Mean x 100 
                          Precision can be considered as having a within assay batch component or 
repeatability which defines the ability to repeat the same methodology with the same analyst, 
using the sesame equipment and same reagents in a short interval of time, e.g. within a day. This 
is also known as intra-assay precision.     
              The ability to repeat the same methodology under different conditions, e.g. change of 
analyst, reagent or equipment, or on subsequent occasions, e.g. across several weeks or months, 
is covered by the between batch precision or reproducibility, also known as inter-assay precision.  
The reproducibility of a method is of most interest to the analyst since this will give better 
representation of the precision during routine use as it includes the variability from many 
sources.  
(e) Accuracy 
            Accuracy normally refers to the difference between the mean x****, of the set of results 
and the true to correct value of the quantity measured. According to IUPAC accuracy is to the 
difference between results (or mean) and the true value. For analytical methods, there are two 
possible ways of determining the accuracy, absolute method and comparative method. 
 
 
Accuracy is best report as percentage bias, which is calculated from the expression       
 
 
 
              (Measured value – True value) 
          %Bias =          True value                               x 100           
True value 
           
        Since for real samples the true value is not known, an approximation is obtained based on 
spiking drug – free matrix to a nominal concentration. The accuracy of analytical method is then 
determined at each concentration by assessing the agreement between the measured and nominal 
concentrations of the analytes in the spiked drug – free matrix sampler. 
 
(f). Limit of detection (LOD) 
           The limit of detection (LOD) of an analytical method may be defined as the concentration, 
which gives rise to an instrument signal that is significantly different from the blank. For 
spectroscopic techniques or other methods that rely upon a calibration curve for quantitative 
measurements, the IUPAC approach employs the standard deviation of the intercept (Sd), which 
may be related to LOD and the slope of the calibration curve, b  
         
LOD = 10 x Standard deviation/slope 
 
(g). Limit of Quantitation (LOQ) 
   The LOQ is the Concentration that can be quantitate reliably with a specified level of 
accuracy and precision. The LOQ represent the Concentration of analyte that would yield a 
signal-to-noise ratio of 10. 
                     LOQ = 10 ×Standard deviation /slope (or) Sa /b 
    
   Where Sd- the estimate is the standard deviation of the peak are ratio of analyte to IS (5 
injections) of the drugs. b -is slope of the corresponding calibration curve. 
Based on Standard Deviation of the blank 
          Measurement of the magnitude of analytical background response is performed by 
analyzing an appropriate number of blank samples and calculating the standard deviation of 
these responses.          
Based on the calibration curve 
          A specific calibration curve should be studied using samples, containing an analyte in the 
range of QL. The residuals SD of regression line or the S.D of intercepts of regression lines may 
be used as the S.D. The quantitative limit is a parameter of quantitative assay for low levels of 
compounds in sample matrices, and is use particularly for the determination of impurities or 
degradation products. 
h). Ruggedness  
          Degree of reproducibility of test results obtained by the analysis of the same samples under 
a variety of condition such as different laboratories, different analysts, different instruments etc, 
normally expressed as the lack of influence on test results of operational and environmental 
variable of the analytical method.  
         Ruggedness is a measurement of reproducibility of test results under the variation in 
condition normally expected from laboratory to laboratory and from analyst to analyst. Degree of 
representative of test results is then determined as a function of the assay variable. 
                       By analysis of aliquots from homogenous lots in different laboratories, by 
different analyst, using operational and environmental conditions that may differs but are still 
within the specified parameter of the assay variable. 
 
 i). Robustness 
       Robustness of an analytical method is measure of its capacity to remain unaffected small but 
deliberate variations in method parameters and provides an indication of its reliability during 
normal usage. 
Testing varying some or all condition: 
-Column temperature 
-PH of buffer in mobile phase 
-Reagents and flow rate 
 
   HPLC method validation:  Everyday many chromatographers face the need to develop a 
HPLC separation whereas individual approaches may exhibit considerable diversity; method 
development often follows the series of steps summarized in the following fig 
                     Steps involved in HPLC method validation 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
  
 
 
 
            1. Introduction on sample 
                 Define separation goals 
          2.  Need    for    special   HPLC 
       Procedure, sample, pretreatment, etc 
      3. Choose detector and   
         Detector settings 
       4. Choose LC method; 
      Preliminary run; estimate best 
          5. Optimize separation                                                                               
condition 
6. Check for problems or requirements 
             for special procedure 
7c. Qualitative 
         Method 
7b.Quantitative 
     Calibration 
7a. Recover 
purified material 
8. Validation method for release to 
               Routine laboratory 
II. Review of Literature 
1. J.J. Berzas Nevado et al.,(2000)14 Developed Method development and validation for the simultaneous 
determination of fluoxetine and fluvoxamine in pharmaceutical preparations by capillary electrophoresis 
Optimal conditions for the quantitative separation were investigated. A background electrolyte solution 
consisting of 40mMborate buffer adjusted to pH 9.3, hydrodynamic injection and 8 kV of separation 
voltage were used, obtaining in these conditions analysis times lower than 2.5 min. Main aspects of the 
validation method are examined and discussed. Detection limits of 1.0 mg/l for fluoxetine and 
fluvoxamine were obtained.  
 
2. Ibrahim a. Darwish et al.,(2005)15 Developed Three simple and sensitive spectrophotometric Methods 
were developed and validated for determination of the hydrochloride salts of fluoxetine, sertraline, and 
paroxetine in their pharmaceutical dosage forms. These methods were based on the reaction of the N-
alkyl vinyl amine formed from the interaction of the free secondary amino group in the investigated 
drugs and acetaldehyde with each of 3 haloquinones, i.e.,chloranil, bromanil, and 2,3-
dichloronaphthoquinone,to give colored vinyl amino-substituted quinones.The colored products 
obtained with chloranil ,bromanil, and 2,3-dichloronaphthoquinone exhibit absorption maxima at 665, 
655, and 580 nm, respectively.  
 
3. Kanakapura Basavaiah et al.,(2008)6, Carried out A new high performance liquid chromatographic 
(HPLC)method in reverse phase was developed and validated for the determination of olanzapine (OLZ) 
in pharmaceutical formulations. Optimum separation was achieved in less than 10 min using a reversed 
phase Intersil ODS column (150 mm × 4.6 mm, i.d.,particle size 5 mm), and elution was accomplished 
using a mobile phase (0.5 mL/min). Detection was carried out using a UV detector set at 271 nm. A 
rectilinear relationship between mean peak area and concentration of OLZ was observed in the range 
10-200mg/mL, with a detection limit of 3.0 mg/mL and a quantization limit of 8.0 mg/mL. Intra-day and 
Inter-day Precision, and accuracy of the methods have been established according to the current ICH 
guidelines. 
 
 
 
4. CR Shah et al.,(2008)9 Carried out A rapid, selective and stability-indicating high performance thin 
layer chromatographic method was developed and validated for the simultaneous estimation of 
olanzapine and fluoxetine in combined tablet dosage form. Olanzapine and fluoxetine were 
chromatographed on silica gel 60 F 254 TLC plate using methanol: toluene (4:2 v/v) as the mobile  
Phase and spectro densitometric scanning-integration was performed at a wavelength of 233 nm using a 
Camag TLC Scanner III. This system was found to give compact spots for both olanzapine (R f value of 
0.63±0.01) and fluoxetine (R f value of 0.31±0.01). The polynomial regression data for the calibration 
plots showed good linear relationship with r 2 =0.9995 in the concentration range of 100-800 ng/spot for 
olanzapine and 1000-8000 ng/spot for fluoxetine with r 2 =0.9991. The method was validated in terms of 
linearity, accuracy, precision, recovery and specificity. 
 
5. Sejal Patel and N. J. Patel et al.,(2009)
22
 Developed Simultaneous RP-HPLC and HPTLC 
Estimation of Fluoxetine Hydrochloride and Olanzapine in Tablet Dosage Forms A binary 
mixture of fluoxetine HCl and olanzapine was determined by two different methods. The first 
method involved determination of fluoxetine HCl and olanzapine using reversed-phase liquid 
chromatography using acetonitrile: methanol: 0.032 M ammonium acetate buffer (45:05:50, 
v/v/v) as the mobile phase at a flow rate of 1.5 ml/min. Quantitation was achieved with 
ultraviolet detection at 235 nm over concentration ranges of 0.2-4 and 0.1-2 μg/ml; mean 
accuracies were 101.16±0.59 and 99.79±0.56% for fluoxetine HCL and olanzapine, 
respectively. 
 
 6. Sandeep B. Patil et al.,(2009)10 Carried out preparation of Olanzapine, quick dispersing tablets by 
direct compression method. Effect of super disintegrant cross povidone on wetting time, disintegration 
time, and drug content and in vitro release have been studied. A 32 factorial Design was employed 
informulating a quick dispersible tablet. The selected independent variables crospovidone and hydroxyl 
propylcellulose showed significant effect on dependent variables i.e.  
Disintegration time and percent drug dissolved. Disintegration time and percent drug dissolved 
decreased with increase in the level of cross povidone. The similarity factor f2 was found to be 72.68 for 
the developed formulation indicating the release was similar to that of the marketed formulation. 
 
 
7. Prameela rani.et al., (2009)13 Carried out A reverse phase HPLC method is developed for the 
determination of olanzapine in pharmaceutical dosage forms. Chromatography was carried out on an 
inertsil C18 column using a mixture of ammonium phosphate buffer and methanol (70:30 v/v) as the 
mobile phase at a flow rate of 1 ml/min. Detection was carried out at 220 nm .The retention time of the 
drug was 3.447min. The method produced linear responses in the concentration range of 2 to 10μg/ml of 
olanzapine. The method was found to be applicable for determination of the drug in tablets. 
 
8. M. Jagadeeswaran et al., (2009)21 Developed A simple, accurate, low cost and specific HPTLC method for 
estimation of Fluoxetine in capsule has been developed. It was performed on Silica gel G60 F254 
aluminum foil using acetonitrile: chloroform in the ratio of 1:9 as mobile phase. The mobile phase having 
chamber was saturated for 15 minutes at room temperature. The Rf value of Fluoxetine was found to be 
0.4. The plate was scanned and quantified at 254 nm. The calibration curve response was observed 
between 4-20 μg. The linear regression data showed good linear relationship of r = 0.9986. The percent 
recovery was found to be 100.0 ± 0.01.The developed method was validated for its accuracy and 
precision with suitable parameters. 
 
9. Deepa Sharma et al.,(2010)7 carried out Simultaneous estimation of risperidone, olanzapine and  
quetiapine and their degradation products by HPLC . A rapid, specific reversed phase HPLC method has 
been developed for simultaneous determination of risperidone, olanzapine and quetiapine. Drugs were 
subjected to stress conditions such as acidic, alkaline and oxidative Hydrolysis. Chromatographic 
separation of these pure drugs was carried out on Luna C18 (250*4.6, 56m) with a 50:50 (v:v)mixture of 
20mM ammonium acetate and acetonitrile as Mobile phase. The flow rate was 1.0 mL min-1 and the 
analysis was monitored at 235 nm by UV detection. The system and method precision was found to be 
less than 1%. The assay results were linear from 35 to 65 μg mL=1 for risperidone (R2 > 0.991), 
olanzapine (R2 > 0.992) and quetiapine (R2> 0.999). Method validated showed it to be specific, precise, 
robust and linear over the range of analysis.  
 
10. Zahid Zaheer et al.,(2010)16 Developed  A simple, accurate, low cost and specific HPTLC method for 
estimation of Fluoxetine hydrochloride in capsule has been developed. It was performed on Silica gel G
60 
F
254 
aluminum foil using Acetone: Methanol in the ratio of 5:4 as mobile phase. The mobile phase 
containing chamber was saturated for 10 minutes at room temperature. The Rf value of Fluoxetine was 
found to be 0.12. The plate was scanned and quantified at 226 nm. 
 11. Moinuddin r syed et al.,(2010)18 Developed A simple and reproducible method was developed for the 
assay of paroxetine in tablets. The excipients in the commercial tablet preparation did not interfere with 
the assay. Beer’s law is obeyed in the range 2.0 ‐ 10.0 μg.mL–1 at .max 294 nm. The molar absorptivity 
was calculated. Six triplicate analyses of solutions containing six different concentrations of the 
examined drug were carried out and gave a mean correlation coefficient 0.999.The proposed method 
was applied to the determination of the examined drug in market tablet and the results demonstrated 
that the method isequally accurate, precise and reproducible as the official methods. 
 
12. Poornachander Thatipalli et al.,(2010)11 Carried out HPLC analysis of olanzapine , a known anti-
psychotic drug, showed impurity peaks ranging from 0.05 to 0.15 % during process development. These 
samples were analyzed by LCMS and the peaks were identified at m/z 230, 341, 511, 326, 361 and 329. 
All six impurities were synthesized individually and characterized based on their spectral data (IR, NMR 
and Mass).  
 
13. Vijaykumar K. Parmar et al., (2011)4 Developed  spectrophotometric determination of 
fluoxetine hydrochloride and olanzapine in tablets . Fluoxetine hydrochloride (FH) in 
combination with Olanzapine (OZ) is used in treatment of depressive episodes associated with 
bipolar disorder. The first derivative spectrophotometric method for simultaneous determination 
of fluoxetine hydrochloride (FH) and olanzapine (OZ) from two component tablet dosage form 
has been developed and validated. Chromatographic methods viz. HPLC and HPTLC methods 
were reported in the literature for the simultaneous determination of FH and OZ from combined 
dosage forms. In the present investigation an attempt has been made to develop accurate, 
reproducible, rapid and cost-effective method for simultaneous determination of FH and OZ in 
pharmaceutical formulation. The wavelengths selected for determination of FH and OZ is 
235.5nm and 296nm, respectively.  
 
 
14. Eirik Kjelby et al.,(2011)8 Carried out Efficacy studies indicate anti-depressive effects of at least some 
second generation antipsychotics(SGAs). The Bergen Psychosis Project (BPP) is a 24-month, pragmatic, 
industry-independent, randomized, head-to head comparison of olanzapine, quetiapine, risperidone and 
ziprasidone in patients acutely admitted with psychosis. The aim of the study is to investigate whether 
differential anti-depressive effectiveness exists among SGAs in a clinically relevant sample of patients 
acutely admitted with psychosis. 
 
 
15. R. Satheesh Kumar et al.,(2011)19 Developed Spectrophotometric method is a simple technique for 
determination of fluoxetine in bulk drug and its pharmaceutical formulation. Fluoxetine is mainly used 
as antidepressant. Fluoxetine shows maximum absorbance at 261nm in Distilled water. Beer’s law 
obeyed concentration range of 400mcg/ml-800mcg/ml with the correlation coefficient of 0.9994. The 
results of analysis were validated statically and by recovery studies and found to be satisfactory. The 
proposed method was extended to pharmaceutical formulations and there was no interference of 
additives and excipients.  
 
 
16. Jordana S. Bueno et al.,(2011)20 Developed  the enantio selective analysis of fluoxetine and 
norfluoxetine in plasma samples was performed by the protein precipitation method and high 
performance liquid chromatography with fluorescence detection (PP/LC-FD). Different 
precipitating agents - organic solvents, acids, and salts - in several proportions were available. 
The Bradford colorimetric method employed for evaluation of the efficiency of protein 
precipitation, has shown that for the sake of simplicity and percentage of protein precipitation 
(99.7%), acetonitrile was most effective when added at a ratio of 3:1 (acetonitrile/plasma, v/v). 
The quantification limit of the PP/LC-FD method was 30 ng mL−1 for the four enantiomers.  
 
 
 
 
 
 
  
 3.1 Aim and objective 
Aim: 
The aim is  to develop and validate a new, simple, accurate, precise and rapid method for 
simultaneous Olanzapine and Fluoxetine Hcl by RP-HPLC.s 
Objective: 
The pharmaceutical companies are manufacturing multiple drug formulations to meet the 
market demand and to treat the patients who are unresponsive to single drug formulations. Very 
few methods are available for simultaneous estimation of multiple drug formulations.  
Standard analytical procedure for simultaneous estimation of multiple drug formulations 
may not be available in pharmacopoeias; hence it is essential to develop newer analytical 
methods which are accurate, precise, specific, linear, simple and rapid. 
From the literature survey it has been concluded that several method were reported for 
estimation of Olanzapine and Fluoxetine Hcl individually  and few methods are available for 
simultaneous estimation of these drugs but none of the reported analytical methods describe a 
method for the simultaneous determination of Olanzapine and Fluoxetine Hcl having less run 
time with good resolution. 
Hence, the present work was thought to develop a precise, accurate, simple and reliable, 
less time consuming method for simultaneous estimation of Olanzapine and Fluoxetine Hcl by 
RP-HPLC. 
 
 
 
 
 
 
PLAN OF WORK 
In present study, an attempt has been made to developed RP-HPLC method for the 
simultaneous estimation of Olanzapine and Fluoxetine HCl in their combined dosage form. 
 Literature survey 
 Selection of λmax 
 Selection of Mobile Phase 
 Selection of Column 
 Method development & Optimization 
 Method of Validation   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                 3.3 MATERIALS 
       3.3.1 Chemicals used: 
S.No Chemicals Grade Manufacturer/Supplier 
1. Water  HPLC Microlabs 
2. Methanol  HPLC Merck  
3. Acetonitrile  HPLC Merck  
4. Potassiumdihydrogen 
phosphate 
AR Merck  
5. Sodium dihydrogen phosphate AR Merck  
6. 0.1M Sodium hydroxide AR Merck  
7. Hydrochloric acid AR Merck  
8. Triethylamine  AR Spectrochem 
9. Ortho phosphoric acid AR Merck  
  
           3.3.2 Equipment used: 
S.No  Name Model  Manufacturer/Supplier 
1. Analytical balance Unibloc Shimandzu, Libror 
2. pH meter Eutech  Shimandzu. 
3. HPLC LC-2010 Shimandzu Corporation, Japan 
4. UV UV-2550 Shimandzu Corporation 
 
    
   Drug sample  
 Olanzapine, Fluoxetine Hcl sample obtained from Chandra labs Pvt., Ltd., Hyderabad.                                                                                                                              
Formulation used 
              Prandimet tablets containing 10 mg Olanzapine and Fluoxetine Hcl 20 mg were proceed 
from Chandra labs Pvt., Ltd., Hyderabad.                   
Solubility 
 Solubility of drugs was observed by dissolving it in different solvents and it was found that 
drugs having good solubility in following solvents. 
 
Table No 4: 
 
S.no 
  
      Solvent 
Solubility 
            Olanzapine Fluoxetine HCl 
1. Water + + 
2. Acetonitrile + + 
3. 0.1N NaOH + + 
4. 0.1N HCl + + 
 
 
 
 
 
 
 
 
 
 
3.4 METHOD DEVELOPMENT 
3.4.1 TRAIL-1 
1. Preparation of Buffer: 
Take 295mg potassium dihydrogen phosphate of 0.02 M  was dissolved in 100ml of water and 
adjust the pH-3 using diluted O-phosphoric acid. 
2. Preparation of mobile phase: 
Filtered and degassed mixture of acetonitrile: buffer in the ratio of 50:50 and filter through 0.45 micron 
membrane filter. 
 
Fig: 1 Olanzapine and Fluoxetine HCl (Acetonitrile: Potassium Di Hydrogen Phosphate Buffer (50:50 V/ 
V)) 
 
 
 
 
 
 
3.4.2 TRAIL-2 
1. Preparation of Buffer: 
 Take 295 mg of 0.02 M   potassium dihydrogen phosphate was dissolved in 100ml of water and 
adjust the pH-4.5 using diluted O-phosphoric acid. 
2. Preparation of mobile phase: 
Filtered and degassed mixture of acetonitrile: buffer in the ratio of 40:60 and filter through 0.45 micron 
membrane filter. 
 
 
Fig: 2 Olanzapine and Fluoxetine HCl (Acetonitrile: Potassium Di Hydrogen     Phosphate Buffer 
(40:60 V/ V)) 
 
 
 
 
 
 
 3.4.3 TRAIL-3 
1. Preparation of Buffer: 
 Take 54 mg of 0.03 M of dipotassium hydrogen phosphate and 295 mg of 0. 02 M of potassium 
di hydrogen phosphate was dissolved in 1000ml of water and adjust the pH-3 using diluted O-
phosphoric acid. 
2. Preparation of mobile phase: 
Filtered and degassed mixture of acetonitrile: buffer in the ratio of 40:60 and filter through 0.45 micron 
membrane filter. 
  
 
Fig: 3 Olanzapine and Fluoxetine HCl (Acetonitrile: Mixed Phosphate Buffer 
     (40:60 V/ V)) 
 
 
 
3.4.4 TRAIL-4 
1. Preparation of Buffer: 
Take 54 mg of 0.03 M of dipotassium hydrogen phosphate and 295 mg of 0.02 M potassium 
dihydrogen phosphate was dissolved in 1000ml of water and adjust the pH-6 using diluted O-
phosphoric acid. 
2. Preparation of mobile phase: 
Filtered and degassed mixture of acetonitrile: buffer in the ratio of 50:50 and Filter through 0.45 micron 
membrane filter. 
 
Fig: 4 Olanzapine and Fluoxetine HCl (Acetonitrile: Mixed Phosphate Buffer (50:50  V/ V)) 
 
 
 
 
 
 
 
 
3.4.5 TRAIL-5 
1. Preparation of Buffer: 
Take 54 mg of 0.03 M of dipotassium hydrogen phosphate and 295 mg of 0.02M potassium 
dihydrogen orthophosphate was dissolved in 1000ml of water and adjust the pH-3 using diluted 
O-phosphoric acid. 
2. Preparation of mobile phase: 
Filtered and degassed mixture of acetonitrile: buffer in the ratio of 45:55 and filter through 0.45 
micron membrane filter. 
 
          Fig : 5 Olanzapine and Fluoxetine HCl  (Acetonitrile: Mixed Phosphate Buffer  
 (45:55 V/ V)) 
 
 
 
 
 
 
3.4.6 TRAIL-6 
1. Preparation of Buffer: 
Take 54 mg of 0.03 M  of dipotassium  hydrogen phosphate and 295 mg of 0.02 M potassium 
dihydrogen phosphate  was dissolved in 100ml of water and adjust the pH-3 using diluted O-
phosphoric acid. 
2. Preparation of mobile phase: 
Filtered and degassed mixture of acetonitrile: buffer in the ratio of 40:55 and Filter through 0.45 micron 
membrane filter. 
TABLE NO 2 : 
Trial Mobile Column Result Wavelength PH FLOW 
1 ACN:KH2PO4 
(50:50) 
WATERS 
SYMMETRY 
C18(250x4.6) 
Asymmetry 
was not good 
 
235 
5.5 1ml/1min 
2 ACN:KH2PO4 
(40:60) 
BDS hypersil 
C18(250x4.6) 
Less retention 
time 
235 4.5 1ml/1min 
3 ACN:KH2PO4 and 
K2HPO4 (40:60) 
WATERS 
C18(250x4.6) 
Asymmetry 
was not good 
235 4.5 1ml/1min 
4 ACN:KH2PO4 and 
K2HPO4 (50:50) 
WATERS 
SYMMETRY 
C18(250x4.6) 
Asymmetry 
was not good 
215 6 1.2ml/1m
in 
5 ACN:KH2PO4 and 
K2HPO4 (45:55) 
WATERS 
SYMMETRY 
C18(250x4.6) 
Optimized 
chromatogram 
235 3 1ml/1min 
6 ACN:KH2PO4 and 
K2HPO4 (45:55) 
WATERS 
SYMMETRY 
C18(250x4.6) 
Good result 235 3 1ml/1min 
 
 
  
 Initialization of the instrument 
Initially, the column was placed on the instrument and switch on the instruments and 
washed with acetonitrile: water (20:80) for 30 min. then the system was made to run with the 
mobile phase for 30 min for column saturation. 
Standard preparation of Olanzapine and Fluoxetine HCl 
Standard-A: Accurately weighed quantity of 10mg Olanzapine was transferred in to a 100 
ml volumetric flask and made up to the volume with diluents. From this 5 ml was pipetted out in 
to a 50 ml volumetric flask and made up to the volume with same diluents. 
Standard-B: Accurately weighed quantity of 20 mg Fluoxetine HCl was transferred in to a 100 
ml volumetric flask and made up to the volume with diluents. From this 5 ml was pipetted out in 
to a 50 ml volumetric flask and made up to the volume with same diluents 
TABLE NO 3: CHROMATOGRAPHIC CONDITIONS 
Mode of operation Isocratic 
Parameters  Description  
Diluents  Water 
Column  C18, 250x4.6mm,5µ SS column 
Mobile phase Acetonitrile: mixed buffer (45:55) 
Flow rate 1.0 ml/min 
Detection of Olanzapine and Fluoxetine HCl 235 nm 
Temperature 250 C 
Injection Volume 20 µl 
Run time 20 min 
Detector  UV detector 
 
 
 3.4.7 TABLE NO : 1 OPTIMIZED METHOD PARAMETERS  
PARAMETERS CONDITIONS 
Column (Stationary Phase) WATERS C18 Symmetry (4.6 x 250mm, 5 m 
Mobile Phase Mixed Buffer: Acetonitrile (55:45) 
Flow rate (ml/min) 
 
1ml/mm. 
Run time (min) 20 
Column temperature(°C) 
25
0 
C 
Volume of injection loop (l) 
20l 
Detection wavelength (nm) 235 
Drug RT (min) 2.2, 5.05 
 
 
 
 
 
 
 
 
3.5 VALIDATION PARAMETERS 
  Since the HPLC method has been developed, validation of method using various parameters   
was performed to ensure that the performance characteristic of the method meets the 
requirements for the intended analytical applications. 
I. SYSTEM  SUITABILITY : 
    Preparation of standard solution: 
Accurately weighed 10 mg olanzapine and 20 mg fluoxetine in 50 ml volumetric flask dilute to 
   Volume with mobile phase volumetric flask dilute to volume with mobile phase. 
 
  Preparation of test solution: 
 
About 0.8500 g of the sample was taken in 100 ml volumetric flask and added 15 ml of mobile   
phase and sonicated for 15 min to dissolve the content and made up to the volume. From this 5 
ml was pipette out into 100 ml volumetric flask and made up to the volume with same mobile 
phase. Filter the content by using 0.45µ membrane filter by applying vacuum. 
 II. SPECIFICITY 
                Specificity is the ability to assess unequivocally an analyte in the presence of 
components that may be expected to be present. For the simultaneous determination of 
olanzapine and fluoxetine HCl the specificity requires that the method should not be affected by 
the presence of other components. Usually the specificity would be performed by allowing the 
sample under stressed conditions. 
i)  Heating  
          For the specificity study 1 mL from the stock solution should be taken in a 10 mL flask, 
make up to the volume with the mobile phase. The solution should be heated at 40 
o
C for a 
period of 30 min. Observe for any degradation occurs or not.  
  
 
 
ii)  Treating with Acids 
         Take 1 mL from the stock solution into a 10 mL flask. To that flask add 1 mL of 0.1M 
hydrochloric acid. Observe for any change took place in the retention of the peak. 
iii) Treating with Base 
          Take 1 mL from stocks solution into a 10 mL flask, and add 1 mL of 0.1 M sodium 
hydroxide. Observe for any degradents. 
III. LINEARITY: 
  Preparation of standard stock solution 
Accurately weighed 10 mg olanzapine and 20 mg fluoxetine in 50 ml volumetric flask dilute to 
volume with mobile phase volumetric flask dilute to volume with mobile phase. 
Preparation of linearity solution-I: Transfer 1ml from stock solution to 10 ml with mobile 
phase(the solution becomes 2mcg of olanzapine and 4mcg of fluoxetine) 
Preparation of linearity solution-II: Transfer 2ml from stock solution to 10 ml with mobile  
phase(the solutionbecomes 4mcg of olanzapine and 8mcg of fluoxetine) 
Preparation of linearity solution-III: Transfer 3ml from stock solution to 10 ml with mobile  
phase(the solution becomes 6mcg of olanzapine and 12mcg of fluoxetine) 
Preparation of linearity solution-IV: Transfer 4ml from stock solution to 10 ml with mobile  
phase(the solution becomes 8mcg of olanzapine and 16mcg of fluoxetine) 
Preparation of linearity solution-V: Transfer 5ml from stock solution to 10 ml with mobile  
phase(the solution becomes 10mcg of olanzapine and 20mcg of fluoxetine) 
Preparation of linearity solution-VI: Transfer 6ml from stock solution to 10 ml with mobile  
phase(the solution becomes 12mcg of olanzapine and 24mcg of fluoxetine) 
 
 
 Determination: The linearity of the analytical method is determined by mathematical 
treatment    of test results obtained by analysis of samples with analyte concentrations across 
the claimed range. Area is plotted graphically as a function of analyte concentration. 
Percentage curve fittings are calculated. 
 Acceptance criteria:  the correlation coefficient and regression coefficient shall be not less 
than 0.99 for Olanzapine and Fluoxetine HCl. 
IV. SYSTEM PRECISION: 
Preparation of Stock solution: 
Weigh 10 mg Olanzapine and 20 mg Fluoxetine in 50 ml Volumetric Flask Dilute To Volume 
with Mobile Phase 
Dilution: 
Transfer 5ml from stock solution to 100 ml with mobile phase (the solution becomes 10mcg of 
olanzapine and 20mcg of fluoxetine) 
V. ACCURACY: 
Preparation of Stock Solution: 
Weigh 10 mg olanzapine and 20 mg fluoxetine in 50 ml volumetric flask dilute to volume with 
mobile phase. 
Preparation of Spiking standard:  
 Transfer 5 ml from stock solution to 100 ml with mobile phase. 
Preparation of Accuracy solution 1: Transfer 4ml from stock solution to 100 ml with mobile 
phase (The solution becomes 8mcg of olanzapine and 16mcg of fluoxetine) and add 1 ml of 
spiking standard.  
 
Preparation of Accuracy solution 2: Transfer 5ml from stock solution to 100 ml with mobile 
phase (The solution becomes 10mcg of olanzapine and 20mcg of fluoxetine) and add 1 ml of 
spiking standard.  
Preparation of Accuracy solution 3: Transfer 6ml from stock solution to 100 ml with mobile 
phase (The solution becomes 12mcg of olanzapine and 24mcg of fluoxetine) and add 1 ml of 
spiking standard. 
VI. METHOD PRECISION: 
Stock solution: 
Weigh 200 mg of the sample In 50 ml Volumetric Flask, Dilute to Volume with Mobile Phase 
Dilution: 
Transfer 5ml from stock solution to 100 ml with mobile phase (the solution becomes 10mcg of 
olanzapine and 20mcg of fluoxetine) 
 
VII. ASSAY:  
Preparation of Stock Solution: 
Weigh 10 mg olanzapine and 20 mg fluoxetine in 50 ml volumetric flask dilute to volume with 
mobile phase. 
Preparation of Standard solution: 
Transfer 5ml from stock solution to 100 ml with mobile phase (The solution becomes 10mcg of 
olanzapine and 20mcg of fluoxetine)   
Preparation of Sample solution: 
Weigh 10 tablets, calculate the average weight, powdered, weigh 200.6mg in 50 ml with mobile 
phase, transfer 5 ml to 100 ml with mobile phase. 
VIII.   LIMIT OF DETECTION (LOD) AND LIMIT OF QUANTIFICATION (LOQ): 
The LOD and LOQ of the drug were derived by visually or calculating the signal-noise ratio. 
In this method the LOD and LOQ of the drug were calculated by following equation. 
   
                      3.3×Standard deviation 
                            LOD =                           Slope 
 
                     10.3×Standard deviation 
                                LOQ =                      Slope 
 
 IX.RUGGEDNESS: 
    Ruggedness study was carried out by repeating the complete experiment with different 
analysts, on different days in same laboratory as per the following preparation. 
    Blank solution: Purity water was used as diluents. 
 Stock solution: 
Weigh 10 mg Olanzapine and 20 mg Fluoxetine In 50 ml Volumetric Flask Dilute To Volume 
With Mobile Phase 
Dilution: 
Transfer 5ml from stock solution to 100 ml with mobile phase (the solution becomes 10mcg of 
olanzapine and 20mcg of fluoxetine) 
Determination: the Ruggedness of the analytical method and instrument is determined by       
assaying sufficient number of samples and relative standard deviation is calculated. 
   Acceptance criteria: the relative standard deviation should not be less than 2 %. 
X. ROBUSTNESS: 
Stock solution: 
Weigh 10 mg Olanzapine and 20 mg Fluoxetine In 50 ml Volumetric Flask Dilute To Volume 
With Mobile Phase 
Dilution: 
Transfer 5ml from stock solution to 100 ml with mobile phase (the solution becomes 10mcg of 
olanzapine and 20mcg of fluoxetine) 
S. No Chromatographic 
condition 
Low  High  
1. Flow rate  0.9 ml 1.1 ml 
2. Wavelength  233 nm 237nm 
 
  Determination: the robustness of an analytical method is to determine by analysis of aliquots 
from homogenous lots by differing physical parameters that may differ but are still within the 
specified parameters of the assay.  
  Acceptance criteria: the percentage assay of drugs should be within the limit of 90- 110%. 
 
 
 
 
 
 
 
 
 
IV. RESULTS AND DISCUSSION 
 
TRAIL-1 
 
System suitability results 
Olanzapine and Fluoxetine hydrochloride 
1.) Tailing factor obtained from trail- 1 was 1.700 and 1.412 
2.) Theoretical plates obtained from trail-1 was 3562 and 4798 
3.) Resolution obtained from trail-1 was 8.843   
4.) Retention time obtained from trail-1 was 2.367 and 4.120 
 
TRAIL-2 
System suitability results 
Olanzapine and Fluoxetine hydrochloride 
1.) Tailing factor obtained from trail- 1 was 2.909 and 2.458 
2.) Theoretical plates obtained from trail-1 was 2795 and 3635 
3.) Resolution obtained from trail-1 was 7.513   
4.) Retention time obtained from trail-1 was 5.690 and 9.733 
 
TRAIL-3 
       System suitability results 
      Olanzapine and Fluoxetine hydrochloride 
1.) Tailing factor obtained from trail- 1 was 2.893 and 2.800 
2.) Theoretical plates obtained from trail-1 was 1714 and 1215 
3.) Resolution obtained from trail-1 was 4.464   
4.) Retention time obtained from trail-1 was 2.990 and 4.887 
 
 
 
TRAIL-4 
System suitability results 
Olanzapine and Fluoxetine hydrochloride 
1.) Tailing factor obtained from trail- 1 was 1.950 and 1.533 
2.) Theoretical plates obtained from trail-1 was 2730 and 7796 
3.) Resolution obtained from trail-1 was 14.454   
4.) Retention time obtained from trail-1 was 2.220 and 5.127 
 
 
TRAIL-5 
System suitability results 
Olanzapine and Fluoxetine hydrochloride 
1.) Tailing factor obtained from trail- 1 was 2.579 and 3.417 
2.) Theoretical plates obtained from trail-1 was 3150 and 5718 
3.) Resolution obtained from trail-1 was 13.581   
4.) Retention time obtained from trail-1 was 2.543 and 5.890 
 
TRAIL-6 
System suitability results 
Olanzapine and Fluoxetine hydrochloride 
1.) Tailing factor obtained from trail- 1 was 1.5 and 1.4 
2.) Theoretical plates obtained from trail-1 was 2500 and 7020 
3.) Retention time obtained from trail-1 was 2.2 and 5.05 
 
 
 
TRAILS RESULT  
       On the evaluation of above system suitability results, 
 In trail-II and trail-III  the   tailing factor is more than 2 so it is not satisfactory 
 In trail III theoretical plates should to be increased. 
 In trail-IV and trail-V the resolution should to be reduced. 
 System suitability parameters of trail-VI were within the satisfactory limits.  
 Hence trail I,II, III,IV,V shows variation  in system suitability results  and  affected the method  
significantly .Trail-VI  shows  good system suitability results and  also within in the limit so the 
trail – VI was adopted. 
VALIDATION RESULTS 
SYSTEM SUITABILITY  
      Table no 5: System suitability results for olanzapine: 
S.No Parameter Olenzapine 
1 RT(min)  
2.2 
2 Tailing Factor 1.5 
3 No.of  theoretical 
plates 
 
2557.000 
 
  Table no 6:  System suitability results for Fluoxetine HCl: 
S.No Parameter Fluoxetine HCl 
1 RT(min)  
5.05 
2 Tailing Factor 1.4 
3  No.of theoretical 
plates 
 
7051.000 
 
Result: 
On the evaluation of above results it was found that all the system suitability parameters were 
within the satisfactory limit. 
SPECIFICITY 
Diluents, standard preparation and assay were prepared as per the method and the solutions were 
injected into the chromatograph and the chromatograms recorded. The retention time given in the 
following table, 
         Table no-7: Specificity results for Olanzapine and Fluoxetine hydrochloride 
S.NO SOLUTION RETENTION TIME(min) 
1. Olanzapine Standard preparation                    2.23 
2. Olanzapine assay preparation                   2.01 
3. Fluoxetine Hcl standard preparation                   5.05 
4. Fluoxetine Hcl assay preparation                   5.02 
 
Table no-8    Specificity results for Olanzapine and Fluoxetine hydrochloride under   stress      
conditions 
 
Result: 
i.) No peaks should be detected at the retention time of Olanzapine and Fluoxetine hydrochloride 
in the chromatograms of diluents preparation  
ii.) From the stress conditions performed, various degradation products were formed and there 
was no change in the detection of the analyte in the presence of other components. 
 
S.NO STRESS CONDITIONS OBSERVED RESULT 
1. Heated on water bath No degradation occurred 
2. Treated with acids No change in retention of the 
peak 
3. Treated with base No degradents formed 
LINEARITY  
TABLE NO 9: Linearity Results: (for olanzapine) 
 
Acceptance Criteria:  Correlation coefficient should be not less than 0.9 
  
y = 16.574x + 2.9281 
R² = 0.9993 
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Conc 
Linearity Of Olanzapine 
 
S.No Linearity Level Concentration Area 
1 I 2 mcg 
34.565 
2 II 4 mcg 
69.423 
3 III 6 mcg 102.909 
4 IV 8 mcg 
138.428 
5 V 10 mcg 
167.979 
6 VI 12 mcg 
200.359 
Correlation Coefficient 0.999 
 CALIBRATION PLOT FOR OLANZAPINE 
 TABLE NO 10 Linearity Results: (for fluoxetine) 
S.No 
Linearity 
Level 
Concentration Area 
1 I 4 mcg 21.437 
2 II 8 mcg 
41.825 
3 III 12 mcg 62.651 
4 IV 16 mcg 
83.335 
5 V 20 mcg 
101.31 
6 VI 24 mcg 
119.966 
Correlation Coefficient 0.999 
 
 
Acceptance Criteria: Correlation coefficient should be not less than 0.9 
 
y = 4.9413x + 2.5756 
R² = 0.9991 
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Conc 
Linearity of Fluoxetine 
CALIBRATION PLOT FOR FLUOXETINE 
DISCUSSION 
On evaluation of above results % RSD values are within the limit hence the curve shows     
linearity. 
                                       
                         
                                               SYSTEM PRECISION  
                      TABLE NO 11- The results are summarized (olanzapine) 
Injection Area 
Injection-1 175.486 
Injection-2 172.348 
Injection-3 173.659 
Injection-4 172.838 
Injection-5 172.537 
Average 173.3736 
Standard 
Deviation 1.282801 
%RSD 0.74 
 
 
 
 
TABLE NO 12 - The results are summarized (fluoxetine) 
 
Injection Area 
Injection-1 104 
Injection-2 104.755 
Injection-3 103.428 
Injection-4 104.507 
Injection-5 104.583 
Average 104.2546 
Standard Deviation 0.540842 
RSD 0.52 
 
 
 Acceptance Criteria: 
The % RSD for the area of five standard injections results should not be more than 2% 
DISCUSSION: 
On the evaluation above results % RSD values are within the limit hence the method is precise. 
 
 
 
ACCURACY 
     TABLE NO 13 - The accuracy results for olanzapine 
%Concentration 
(at specification 
Level) 
Area 
Amount 
Added 
(mcg) 
Amount 
Found 
(mcg) 
% Recovery 
Mean 
Recovery 
80% 154.4297 9 8.93 99.26% 
99.44% 100% 189.5143 11 10.96 99.66% 
120% 223.4167 13 12.92 99.41% 
       
Acceptance Criteria: 
The % Recovery for each level should be between 98.0 to 102.0% 
 
                            TABLE NO 14 – The accuracy results for fluoxetine 
%Concentration 
(at specification 
Level) 
Area 
Amount 
Added 
(mcg) 
Amount 
Found 
(mcg) 
% Recovery 
Mean 
Recovery 
80% 92.97033 18 17.88 99.34% 
99.59% 
100% 113.7897 22 21.89 99.48% 
120% 135.1153 26 25.99 99.95%  
 
Acceptance Criteria: 
 The % Recovery for each level should be between 98.0 to 102.0 
 
DISCUSSITON: 
 On the evaluation above results % recovery of the drug shows 99.5 % hence the method   
is found to be accurate. 
                                             METHOD PRECISION 
                       TABLE NO 15: Method precision results (Olanzapine): 
S.No. Rt  Area 
1 2.21 171.772 
2 2.19 173.657 
3 2.217 173.768 
4 2.2 174.41 
5 2.207 172.398 
avg 2.2048 173.201 
stdev 0.010281 1.081429 
%RSD 0.47 0.62 
 
                           TABLE NO 16: Method precision results (Fluoxetine): 
S.No. Rt Area 
1 5.077 104.183 
2 5.053 104.585 
3 5.097 105.061 
4 5.053 104.819 
5 5.073 104.958 
avg 5.0706 104.7212 
stdev 0.018461 0.349754 
%RSD 0.36 0.33 
 
Acceptance Criteria: 
   The % RSD for the area of five standard injections results should not be more than 2% 
DISCUSSION: 
On the evaluation above results % RSD values are within the limit hence the method is precise. 
ASSAY 
Calculation for olanzapine: 
 
 AT  WS  DT  P Avg.Wt   
-------------------X-----------------X----------------X------------X--------------x100 
 AS  DS  WT  100 Label claim 
 
Where: 
AT = average area counts of sample preparation. 
As= average area counts of standard preparation. 
WS = Weight of working standard taken in mg. 
 
P     = Percentage purity of working standard 
LC =     Label claim of olanzapine mg/ml. 
 173.404 0.01  10  99.7      0.2 
------------- x ----------- x-----------------x-------------------x---------------   =x100=100.02       
 172.8567  10  0.2  100  0.01 
Calculation for fluoxetine hydrochloride 
Assay%= 
 AT  WS  DT  P Avg.Wt     
-------------------X-----------------X----------------X------------X--------------x100 
 AS  DS  WT  100 Label claim 
Where: 
AT = average area counts of sample preparation. 
As= average area counts of standard preparation. 
WS = Weight of working standard taken in mg. 
P     = Percentage purity of working standard 
LC =     LABEL CLAIM OF fluoxetine hydrochloride mg/ml. 
 
                103.681              0.02        20                     99.8       0.2 
            ---------------x-----------------x-------------------x------------------x----------      x 100=99.66                                                          
            104.0327       20                    0.2                     100         0.02  
    RESULT: 
1.) The percentage purity of olanzapine=100.22% 
2.) The percentage purity of fluoxetine hydrochloride=99.66 
LIMIT OF DETECTION: (for olanzapine) 
                                          Std deviation 
                       LOD = 3.3 x     ---------------- 
                                                      Slope 
 
                                              0.008019 
                                = 3.3 x     ---------  
                                                 0.999 
 
                                 =0.29040 µg/ml 
 
LIMIT OF QUANTIFICATION: (for olanzapine) 
                                           Std deviation 
                   LOD = 10.3 x     ---------------- 
                                                      Slope 
 
                                                  0.008019 
                                = 10.3 x        ---------  
                                                       0.999 
 
                                  =0.90600 µg/ml 
 
 LIMIT OF DETECTION: (for Fluoxetine) 
                                                Std deviation 
                       LOD = 3.3 x     ---------------- 
                                                      Slope 
 
                                                   0.02045 
                                = 3.3 x     ---------  
                                                 0.999 
 
                                 =0.36120 µg/ml 
 
LIMIT OF QUANTIFICATION: (for Fluoxetine) 
                                                  Std deviation 
                       LOD = 10.3 x     ---------------- 
                                                      Slope 
 
                                                     0.02045 
                                = 10.3 x        ---------  
                                                       0.999 
 
                                  =1.12720 µg/ml 
 
 
 
 
 
RUGGEDNESS 
Table no -17 intermediate precision (ruggedness) for Olanzapine: 
Injections Area  
 Analyst-1 Analyst-2 
1 174.236 175.224 
2 172.238 172.344 
3 173.244 174.432 
4 173.322 171.238 
5 174.414 173.224 
6 172.314 173.382 
Avg 173.2947 173.3073 
Std dev 0.918758 1.425564 
%RSD 0.52 0.82 
 
Table no -18 intermediate precision (ruggedness) for fluoxetine HCl : 
Injections Area  
 Analyst-1 Analyst-2 
1 105.715 106.734 
2 104.722 105.735 
3 105.744 106.765 
4 103.755 106.788 
5 105.711 105.734 
6 104.760 105.797 
Avg 105.0678 106.089 
Std dev 0.80344 
 
1.336743 
%RSD 0.76 0.84 
 
DISCUSSION: 
The %RSD is less than 2% for the results of two analyst indicating the ruggedness of the method.  
 
 
 
 
ROBUSTNESS: 
The robustness of the method established by making minor variations in the method parameters 
like, change  in flow rate by ± 10 % of actual flow rate . 
 Table no-19 results for Olanzapine 
   
S.No 
 
Flow Rate 
(ml/min) 
System Suitability Results 
USP Plate Count USP Tailing 
1 0.9 3191 1.544 
2       1.1         7037         1.446 
       
 Table no-20  Results for Fluoxetine hydrochloride: 
   
S.No 
 
Flow Rate 
(ml/min) 
System Suitability Results 
USP Plate Count USP Tailing 
1 0.9 7512    1.431 
3      1.1          2772           1.518 
 
Table no-21 results for Olanzapine 
   
S.No 
 
wavelength (nm) 
System Suitability Results 
USP Plate Count USP Tailing 
1 233 2878 1.512 
2       237         7037         1.446 
 
Table no-22 results for Fluoxetine hydrochloride: 
 
   
S.No 
 
wavelength (nm) 
System Suitability Results 
USP Plate Count USP Tailing 
1 233 3022    1.512 
3       237          7151           1.421 
 
       Result: 
  The flow rate was varied at 0.9 ml/min to 1.1ml/min 
On evaluation of the above results, it can be concluded that the variation in flow rate and 
wavelength not affected the method significantly. Hence it indicates that the method is not robust 
even by change in the flow rate and wavelength ±10%. 
 
 
 
 
 
 
 
 
 
 
 
 
  V. SUMMARY AND CONCLUSION 
An attempt has been made to develop the RP-HPLC method for simultaneous estimation 
of Olanzapine and Fluoxetine Hcl in combined dosage form. As the literature survey revealed 
that few methods were available for their simultaneous estimation, but there is a need of a 
simple, economical and proper method for estimation of above combination in combined dosage 
form. 
Water‟s- HPLC with spinchrom 21cfr software, UV detector and with symmetry C18
 
Column 
(250mm X 4.6 mm, 5µ), an injection volume of 20μl is injected and eluted with the mobile phase 
of mixed buffer (0.02M Potassium dihydrogen phosphate +0.03 M diPotassium hydrogen 
phosphate):Acetonitrile (55: 45), which was pumped at a flow rate of 1ml/min and detected by 
UV detector at 235nm. The peaks of Olanzapine and Fluoxetine Hcl were found well separated 
at, 2.2 and 5.1 respectively. 
               The specificity performed shows various degradation products and there is no    change 
in the detection of the analyte in the presence of other components. 
The assay study was found that the formulation contains 100.2% of Olanzapine and 
99.6%.of Fluoxetine Hcl. 
  The system suitability studies was found that all the system suitability parameters were 
within the acceptance criteria. 
The linearity was found that the drug obeys linearity within the concentration range of 2 - 
12g/ml for Olanzapine, 4-24g/ml for Fluoxetine Hcl. 
The results shown in accuracy was found that the percentage recovery values of pure 
drug from the preanalyzed solutions of formulations were in between 99.4% for Olanzapine , 
99.5% for  Fluoxetine Hcl, which indicates that the method was accurate. 
 The result shown in precision was found that % RSD is less than 2%; which indicates 
that the proposed method has good reproducibility.  
 
 The results shown in Robustness were found that there is little change in the results with 
the change in the parameters like flow rate and wavelength, indicating the robustness of the 
method. 
From the results shown in the ruggedness, the %RSD is less than 2% for the results of two 
analyst indicating the ruggedness of the method.  
The developed chromatographic method for the determination of Olanzapine And 
Fluoxetine Hcl in tablet dosage forms was simple, rapid, accurate, precise, specific, robust and 
economical. The mobile phase is simple to prepare and economical reliable, sensitive and less 
time consuming.  
Since the system suitability studies as well as its validation studies have shown 
satisfactory as well, it is deduced that the simple and short proposed method be most useful for 
analysis purpose. 
 
CONCLUSION: 
The present study was validated as per the ICH guidelines. 
From the comparative study, it was inferred that the method is simple, specific, precise, linear, 
sensitive, and also system suitability. The results obtained on the validation parameter met the 
respective acceptance criteria.  
The method was found to have suitable application in routine laboratory analysis and with high 
degree of accuracy and precision. 
From the comprehensive validation conducted, it was concluded that the method is stable and 
could be used throughout shelf life of the drug. 
 
 
 
 VI. CHROMATOGRAM 
SPECIFICITY : 
 Fig : 6 Olanzapine and Fluoxetine HCl 
 
Fig : 7 Olanzapine and Fluoxetine HCl 
          
 
 
         LINEARITY 
Fig : 8 Olanzapine(2 ppm) and Fluoxetine HCl(4 ppm) 
 
Fig : 9 Olanzapine (4 ppm) and Fluoxetine HCl(8 ppm) 
 
 
 
 
Fig : 10 Olanzapine(6 ppm) and Fluoxetine HCl(12 ppm) 
 
 
Fig : 11  Olanzapine(8 ppm) and Fluoxetine HCl(16 ppm) 
 
  
Fig : 12 Olanzapine (10 ppm) and Fluoxetine HCl (20 ppm)  
 
Fig : 13 Olanzapine (12 ppm) and Fluoxetine HCl (24 ppm)         
 
 PRECISION 
Fig : 14 Olanzapine (10 mcg) and Fluoxetine HCl (20 mcg) 
 
Fig : 15 Olanzapine (10 mcg) and Fluoxetine HCl (20 mcg) 
 
                        
 
 
 
 
              
 
 
 
Fig : 16 Olanzapine (10 mcg) and Fluoxetine HCl (20 mcg) 
                                                      
 
Fig : 17 Olanzapine (10 mcg) and Fluoxetine HCl (20 mcg) 
 
 
 
 Fig : 18 Olanzapine (10 mcg) and Fluoxetine HCl (20 mcg) 
 
 
 
 
 
 
 
 
 
 
 
 
 
ASSAY 
Fig : 19 Olanzapine (10 mcg) and Fluoxetine HCl (20 mcg) (Sample) 
 
Fig : 20 Olanzapine (10 mcg) and Fluoxetine HCl(20 mcg) (Std) 
 
 Fig : 21 Olanzapine (10 mcg) and Fluoxetine HCl (20 mcg) (Sample) 
 
Fig : 22 Olanzapine (10 mcg) and Fluoxetine HCl (20 mcg) (Std) 
 
 Fig : 23 Olanzapine (10 mcg) and Fluoxetine HCl (20 mcg) (Std) 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACCURACY 
Fig : 24 Olanzapine (9 mcg) and Fluoxetine HCl (18 mcg) 
 
Fig : 25 Olanzapine (11 mcg) and Fluoxetine HCl (22 mcg) 
                
 
Fig : 26 Olanzapine (13 mcg) and Fluoxetine HCl (26 mcg) 
 
Fig : 27 Olanzapine (10 mcg) and Fluoxetine HCl (20 mcg)(Spiking standard) 
 
Fig : 28 Olanzapine (10 mcg) and Fluoxetine HCl (20 mcg)(Spiking standard) 
 
Fig : 29 Olanzapine (10 mcg) and Fluoxetine HCl (20 mcg)(Spiking standard) 
 
METHOD PRECISION 
Fig : 30 Olanzapine (10 mcg) and Fluoxetine HCl (20 mcg)
 
Fig : 31 Olanzapine (10 mcg) and Fluoxetine HCl (20 mcg)
 
Fig : 32 Olanzapine (10 mcg) and Fluoxetine HCl (20 mcg) 
 Fig : 33 Olanzapine (10 mcg) and Fluoxetine HCl (20 mcg) 
 
 
Fig : 34 Olanzapine (10 mcg) and Fluoxetine HCl (20 mcg) 
  
 
 
 
 
 
 
 
 
 
 
 
 
RUGGEDNESS 
Fig : 35 Olanzapine (10 mcg) and Fluoxetine HCl (20 mcg) 
 
Fig : 36 Olanzapine (10 mcg) and Fluoxetine HCl (20 mcg) 
 
 
ROBUSTNESS 
Fig : 37 Olanzapine (10 mcg) and Fluoxetine HCl (20 mcg) 
 
Fig :38 Olanzapine (10 mcg) and Fluoxetine HCl (20 mcg) 
 
 
Fig : 39 Olanzapine (10 mcg) and Fluoxetine HCl (20 mcg) 
 
Fig : 40 Olanzapine (10 mcg) and Fluoxetine HCl (20 mcg)
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